Published in Immunotherapy Weekly, October 24th, 2007
Imprime PGG is a unique biological response modifier that enhances specific innate immune cell responses without inducing pro-inflammatory cytokines. Erbitux (cetuximab) is a monoclonal antibody from ImClone Systems that is approved for treatment of colorectal and head and neck cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly